Metropolis Healthcare Q2 FY26 Concall Decoded β Clean Tests, Dirty Margins, and a Dose of AI Hope
1. Opening Hook When your annual health check-up costs less than your cab ride to the lab, you know competitionβs gone viral. π§ͺ Amid price wars and post-pandemic malaise, Metropolis somehow pulled a 23% revenue growth β and still had breath left to brag about AI chatbots and βgenomic synergies.β Chairman Ameera Shah called it βsteady growth,β but it felt more like a well-timed caffeine rush. With B2C at 59% and Core Diagnostics integration still in ICU, the companyβs trying to prove itβs not just another blood test factory. Stick around β this call had more tech talk than a startup pitch.
2. At a Glance
Revenue up 23%: Doctorsβ prescriptions may slow, but Metropolis didnβt skip its growth meds.
Ameera Shah: βWe are building a resilient, future-ready diagnostics company.β (Translation: Weβve said this for five years, but this time weβve added AI.) π
Surendran Chemmenkotil: βMargins improved by 60 bps YoY to 26.8%.β (Translation: Weβve upgraded from mild anemia to stable vitals.)
Sameer Patel: βCore Diagnostics moved from breakeven to high-single-digit margins.β (Translation: Still in rehab, but at least the patientβs breathing.)
Ameera Shah: βNo new acquisitions for 6β9 months; focus on organic growth.β (Translation: Wallet says stop, strategy says spin it as discipline.)
Surendran: βAdded 200 new centres, 300 more coming.β (Translation: When in doubt, expand faster than your margins.)
Ameera Shah: βWeβre integrating AI for productivity and customer experience.β (Translation: The robots canβt draw blood yet, but they can schedule your test politely.)
Ameera Shah: βOur moat is quality, accessibility and empathy.β (Translation: The moatβs still being dug, but at least the PRβs ready.)
4. Numbers Decoded
Source table
Metric
Q2 FY26
YoY Growth
Comment
Revenue (Group)
βΉ429 Cr
+23%
Strong mix of TruHealth, Specialty, and mild fever season help.